Turn Therapeutics (NASDAQ:TTRX) Cut to "Sell" at Wall Street Zen

Turn Therapeutics logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Wall Street Zen downgraded Turn Therapeutics from “hold” to “sell,” adding a bearish view amid mixed analyst opinions.
  • Despite the downgrade, MarketBeat’s consensus rating remains “Moderate Buy,” with an average price target of $9.00; analysts’ ratings range from Strong Buy to Sell.
  • Turn Therapeutics reported a quarterly loss of $0.20 per share, and analysts expect a full-year loss of $0.40 per share.
  • MarketBeat previews top five stocks to own in December.

Turn Therapeutics (NASDAQ:TTRX - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued on Sunday, Wall Street Zen reports.

A number of other equities research analysts have also recently commented on the stock. Lucid Cap Mkts upgraded shares of Turn Therapeutics to a "strong-buy" rating in a report on Thursday, September 24th. WBB Securities upgraded shares of Turn Therapeutics from a "sell" rating to a "hold" rating and set a $10.00 price objective for the company in a report on Friday, October 23rd. Zacks Research raised Turn Therapeutics to a "hold" rating in a research report on Tuesday, July 21st. LADENBURG THALM/SH SH upgraded Turn Therapeutics to a "strong-buy" rating in a research note on Monday, July 20th. Finally, Weiss Ratings lowered Turn Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a report on Tuesday, August 18th. Two equities research analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $9.00.

Read Our Latest Stock Report on TTRX

Turn Therapeutics Trading Up 6.0%

NASDAQ TTRX opened at $9.48 on Friday. The stock has a 50-day moving average of $11.70 and a 200-day moving average of $7.13. The company has a debt-to-equity ratio of 8.83, a current ratio of 1.19 and a quick ratio of 1.19. Turn Therapeutics has a 1-year low of $2.57 and a 1-year high of $16.45.

Turn Therapeutics (NASDAQ:TTRX - Get Free Report) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.20) EPS for the quarter. Research analysts expect that Turn Therapeutics will post -0.40 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Turn Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in TTRX. Ieq Capital LLC bought a new position in shares of Turn Therapeutics during the 2nd quarter valued at $1,660,000. Bridgewater Advisors Inc. bought a new stake in shares of Turn Therapeutics in the second quarter worth $242,000. TD Waterhouse Canada Inc. bought a new stake in shares of Turn Therapeutics in the third quarter worth $40,000. SteelPeak Wealth LLC increased its position in Turn Therapeutics by 0.7% during the third quarter. SteelPeak Wealth LLC now owns 251,275 shares of the company's stock valued at $3,616,000 after acquiring an additional 1,819 shares during the last quarter. Finally, Jefferies Financial Group Inc. purchased a new stake in Turn Therapeutics during the second quarter valued at $119,000.

About Turn Therapeutics

(Get Free Report)

Turn Therapeutics, Inc is a biotechnology and pharmaceutical company focused on developing topical therapies for skin and wound-care applications. The company's platform is designed to support the delivery of therapeutic compounds to the skin while helping address microbial contamination and other complications associated with wounds.

Turn Therapeutics has identified MVT-100 as a lead product candidate. The topical formulation is intended for use in wound-care settings, including the management of chronic and difficult-to-heal wounds.

See Also

Analyst Recommendations for Turn Therapeutics (NASDAQ:TTRX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Turn Therapeutics Right Now?

Before you consider Turn Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Turn Therapeutics wasn't on the list.

While Turn Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines